H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT

CG Oncology, Inc. (NASDAQ:CGON) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 11, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on CG Oncology, Inc. (NASDAQ:CGON) with a price target of $75.

The analyst noted that the company is making good progress with its drug Cretostimogene for treating BCG-unresponsive high-risk non-muscle invasive bladder cancer. Data from the ongoing studies is expected by the end of 2025, which Maldonado believes will be a key milestone. In addition, the BOND-003 study shows a strong median duration of response, which is supported by stable immune system activity, indicating long-term control of the disease.

Maldonado highlighted that CG Oncology, Inc. (NASDAQ:CGON) is improving its drug administration and stability, which makes it easier for urologists to adopt the treatment. Moreover, the analyst sees faster patient enrollment in trials and growing market awareness as positive signs for the company.

CG Oncology, Inc. (NASDAQ:CGON) is a biotechnology company that develops treatments for bladder cancer, focusing on bladder-sparing therapies.

While we acknowledge the potential of CGON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.